In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas.

Christel Larbouret 1 Bruno Robert 1 Isabelle Navarro-Teulon 1 Simon Thèzenas 2 Maha-Zohra Ladjemi 1 Sébastien Morisseau 1 Emmanuelle Campigna 1 Frédéric Bibeau 3 Jean-Pierre Mach 4 André Pèlegrin 1, * David Azria 1, 5
* Auteur correspondant
1 Immunociblage des Tumeurs et Ingenierie des Anticorps
2 Unité de biostatistiques
3 Laboratoire d'anatomo-pathologie
4 Département de Biochimie
5 Département de radiothérapie
Abstract : PURPOSE: Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR) and HER2 have been reported to be both dysregulated in this cancer. To evaluate the in vivo effect of binding both EGFR and HER2 with two therapeutic humanized monoclonal antibodies (mAb), we treated human pancreatic carcinoma xenografts, expressing high EGFR and low HER2 levels. EXPERIMENTAL DESIGN: Nude mice, bearing xenografts of BxPC-3 or MiaPaCa-2 human pancreatic carcinoma cell lines, were injected twice weekly for 4 weeks with different doses of anti-EGFR (matuzumab) and anti-HER2 (trastuzumab) mAbs either alone or in combination. The effect of the two mAbs, on HER receptor phosphorylation, was also studied in vitro by Western blot analysis. RESULTS: The combined mAb treatment significantly inhibited tumor progression of the BxPC-3 xenografts compared with single mAb injection (P = 0.006) or no treatment (P = 0.0004) and specifically induced some complete remissions. The two mAbs had more antitumor effect than 4-fold greater doses of each mAb. The significant synergistic effect of the two mAbs was confirmed on the MiaPaCa-2 xenograft and on another type of carcinoma, SK-OV-3 ovarian carcinoma xenografts. In vitro, the cooperative effect of the two mAbs was associated with a decrease in EGFR and HER2 receptor phosphorylation. CONCLUSIONS: Anti-HER2 mAb has a synergistic therapeutic effect when combined with an anti-EGFR mAb on pancreatic carcinomas with low HER2 expression. These observations may open the way to the use of these two mAbs in a large panel of carcinomas expressing different levels of the two HER receptors.
Keywords : EGFR HER2 monoclonal antibodies therapeutic synergism pancreatic cancer
Type de document :
Article dans une revue
Clinical Cancer Research, American Association for Cancer Research, 2007, 13 (11), pp.3356-62. 〈10.1158/1078-0432.CCR-06-2302〉
Liste complète des métadonnées

Littérature citée [18 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00153693
Contributeur : Yves Le Ster <>
Soumis le : lundi 5 juillet 2010 - 13:29:34
Dernière modification le : mercredi 11 octobre 2017 - 01:02:01
Document(s) archivé(s) le : mercredi 30 novembre 2016 - 09:45:26

Fichier

In_vivo_therapeutic_synergism_...

Identifiants

Collections

FNCLCC | VALDAURELLE

Citation

Christel Larbouret, Bruno Robert, Isabelle Navarro-Teulon, Simon Thèzenas, Maha-Zohra Ladjemi, et al.. In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas.. Clinical Cancer Research, American Association for Cancer Research, 2007, 13 (11), pp.3356-62. 〈10.1158/1078-0432.CCR-06-2302〉. 〈inserm-00153693〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

277

Téléchargements de fichiers

345

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD